Tagged Articles

type 2 80 articles

Eli Lilly closer to seeking approval for new type 2 diabetes drug

Late stage research on Eli Lilly and Co.’s potential new type 2 diabetes medication dulaglutide shows it was better than two other drugs at lowering blood sugar levels. The drug company says it hopes to apply for approval from United States drug regulators next year, but the timing depends on the completion of Food and Drug Administration (FDA) requirements for an assessment of the drug’s cardiovascular risk. Eli Lilly reported that two injections of dulaglutide lowered blood sugar levels better than twice-daily injections of exenatide and the oral treatments metformin and sitagliptin. More details of the study that provided this ... Read More

Analyst: diabetes drug sales expected to more than double by 2020

Sales of diabetes drugs should keep growing at about 10 percent a year for the rest of the decade, reaching $65 billion a year by 2020, says Jeffrey Holford, an analyst with Jefferies & Co. At that pace, diabetes drug revenues should more than double from the current $30 billion by the decade’s end. Holford says diabetes drug revenues should rise in relation to the aging population in the West, while in emerging markets, diabetes and obesity are increasing and access to health care is also growing. Other factors considered include higher drug prices, strong patent protection for key drugs, ... Read More

FDA to review drugs in new class of type 2 diabetes medications

Two type 2 diabetes drugs in a new class of blood sugar lowering medications known as SGLT2 inhibitors are hoping to win approval from the Food and Drug Administration (FDA) – Johnson & Johnson’s canagliflozin, and empagliflozin, made jointly by Eli Lilly and Boehringer Ingelheim. The drug makers presented the benefits of their medications recently at the European Association for the Study of Diabetes meeting in Berlin. The two drugs are among several of their kind for the treatment of diabetes, and are in various stages of development. The FDA is currently reviewing data for canagliflozin, and it is expected ... Read More

Patients with history of bladder cancer should avoid Actos altogether

Researchers have confirmed a link between a popular class of type 2 diabetes drugs and bladder cancer, Renal & Urology News reports. The drugs are in a class known as thiazolidinediones, which include the brand-name medications Avandia (rosiglitazone) and Actos (pioglitazone). The risk is even greater in patients who use Actos. “Consequently, pioglitazone (Actos) should be avoided in selected high-risk patients,” the medical publication warns. The findings come from a meta-analysis, published in the Canadian Medical Association Journal, aimed at determining the risk of bladder cancer among adults with type 2 diabetes taking this class of diabetes drugs. Type 2 ... Read More

High blood sugar in non-diabetics linked to cognitive decline

Controlling blood sugar levels in could boost memory and emotional processing in non-diabetics, according to a new study published in the journal Neurology. The Australian study involved nearly 250 non-diabetic men and women, and found those with high blood sugar levels tended to have shrinking in specific areas of the brain. Researchers say the results remained consistent even after considerations were made for lifestyle factors such as smoking and weight. Previous research has already linked diabetes to age-related cognitive decline. Diabetes is a condition in which blood sugar levels are abnormally high. Almost all patients with the disease rely on ... Read More

Diabetes drugs Actos, Avandia linked to bladder cancer, heart failure

Actos (pioglitazone) may control blood sugar levels in older diabetics better than metformin, but it still carries risks that patients should weigh before taking the drugs, said a medical expert for AARP.org. Actos is a medication used to treat type 2 diabetes. Actos is similar to Avandia (rosiglitazone), and both drugs are in a class of medications known as thiazolidinediones (TZDs). Whether used alone or with other antidiabetic agents, TZDs can cause or worsen heart failure. In 2010, the Food and Drug Administration (FDA) severely restricted the use of Avandia because of the cardiovascular risk, but the agency did not ... Read More

Paula Deen and sons team up with drug maker to push recipes for diabetics

Paula Deen and her two sons, Bobby and Jamie, are teaming up with drug maker Novo Nordisk for a national initiative aimed at helping diabetics like Paula overcome common challenges associated with type 2 diabetes management. The campaign, called Diabetes in a New Light, features recipes for lighter versions of some of Paula’s favorite summertime recipes. Earlier this year, Paula announced she had been diagnosed with type 2 diabetes three years prior. She chose to come clean about her disease after signing a lucrative deal with Novo Nordisk to promote its type 2 diabetes drug Victoza. The celebrity chef’s announcement ... Read More

Paula Deen’s deal with diabetes drug among ‘Most Questionable’ celebrity chef deals

Huffington Post has named Paula Deen’s deal to promote a type 2 diabetes drug among “The 13 Most Questionable Deals” made by celebrity chefs. “Everyone has to make a living, even celebrity chefs. That disclaimer aside, the last few years have seem more than a few celebrity chef endorsements that raise an eyebrow or three,” the publication reported. “We hear about the most egregious ones in the press – like butter-evangelist Paula Deen’s deal with a diabetes medication that went public just after she announced her own diabetes diagnosis…” Deen’s decision to come clean about her type 2 diabetes diagnosis three ... Read More

Study finds long-term Actos, Avandia use increases risk for bladder cancer

When the Food and Drug Administration (FDA) last year issued a warning that the type 2 diabetes drug Actos (pioglitazone) was shown to increase users’ risk for bladder cancer, its warning was based on limited data from the Kaiser Permanente Northern California diabetes registry, the French national health information system, and the PROspective pioglitazone Clinical Trail In macroVascular Events study. “None of the previous studies directly compared the TZDs (the class of drugs that includes Actos) with sulfonylureas (SUs), the common alternative therapy for type 2 diabetes not adequately controlled with metformin,” says Ronac Mamtani with the University of Pennsylvania. ... Read More

Consumer Reports: Avoid brand name, generic versions of diabetes drug Actos

Consumer Reports, the American consumer products reviewer, is telling its readers to avoid both the brand-name and the new generic versions of the type 2 diabetes drug Actos. “Our medical advisors say that people with diabetes should use pioglitazone, generic or brand-name Actos, only as a last resport,” says the organization’s blog site. Generic versions of Actos, also known by the name pioglitazone, from three different manufacturers became eligible this week to be sold in the United States. The average retail price of brand-name Actos is about $377 for a 30-day prescription. The cost for generics should remain close to the ... Read More